Health Economist

Evaluates the economic impact of healthcare interventions, conducting cost-effectiveness analyses, budget impact models, and health technology assessments to inform reimbursement and formulary decisions.

What does a Health Economist do?

What the work is really like

You build economic models that answer whether a drug, device, or intervention is worth the money. A pharmaceutical company wants to know if their new oncology treatment justifies a $150,000 annual price tag. You construct a Markov cohort model in TreeAge or R, estimate quality-adjusted life years gained, compare costs over a ten-year horizon, and produce an incremental cost-effectiveness ratio that health systems can use. The output matters. It shapes formulary decisions, reimbursement negotiations, and access for thousands of patients.

Most days involve programming models, cleaning real-world evidence datasets, and writing. You pull survival curves from clinical trials, apply utility weights from published literature, discount future costs to present value, and run sensitivity analyses to test how fragile your conclusions are. You write reports for payers, regulatory dossiers for agencies like NICE or CADTH, and manuscripts for journals like *Health Economics* or *Value in Health*. The work is precise and slow. A single model can take weeks to validate.

You collaborate with clinicians, biostatisticians, market access teams, and external consultants. Clinicians help you understand disease progression and treatment patterns, statisticians provide survival models and regression outputs, and market access colleagues translate your findings into pricing strategy. The role sits at the edge of academia and industry, and you translate between both languages constantly.

Skills and strengths that matter

You need technical command of economic modelling. Cost-effectiveness analysis, budget impact models, probabilistic sensitivity analysis, and partitioned survival models are tools you use weekly. Proficiency in R, TreeAge, Excel with VBA, or Stata is expected. You should be comfortable reading Kaplan-Meier curves, hazard ratios, and network meta-analysis outputs, then converting them into model inputs.

Scientific writing carries as much weight as the modelling itself. You write for peer reviewers, health technology assessment bodies, and payers who mistrust complexity they cannot verify. Clarity matters more than cleverness. A well-structured dossier with transparent assumptions and reproducible methods earns trust, while a dense, jargon-heavy document earns rejection.

Analytical rigour is the mindset that keeps you employed. You question every assumption, trace every data source, and document every deviation from best practice guidelines. When a stakeholder asks you to lower a cost estimate or shift a utility weight, you hold the line or you disclose the change explicitly. The profession runs on credibility, and once you lose it with regulators or journals, you do not get it back.

Stakeholder management becomes critical as you advance. You present to senior leadership who want the headline number in two slides, defend your methods to external reviewers who wrote the guidelines you followed, and negotiate scope with clients who want five scenarios modelled in three days. Knowing when to push back and when to adapt the question is learned through repetition and mistakes.

Who tends to thrive here

You thrive if you enjoy problems that require both structure and judgment. The frameworks are well established, but the assumptions are debatable, the data are messy, and reasonable people disagree on discount rates, time horizons, and comparators. If you want single right answers, this will frustrate you. If you want to argue over assumptions with evidence in hand, it will suit you.

The work suits people who can sit with a model for hours without needing external stimulation. You will spend entire afternoons debugging a transition probability matrix or reconciling two conflicting data sources. The reward is an elegant model that holds up under scrutiny, a private satisfaction rather than a public one.

Most health economists come from economics, public health, or epidemiology, and many hold PhDs. The work attracts people who liked research methods courses more than theory seminars, who want applied work without bedside contact, and who find purpose in improving resource allocation rather than treating individuals directly. If you need immediate, visible impact or frequent human interaction, the long feedback loops and solo desk time will drain you.

How people get into the role and grow

The typical entry point is a PhD in health economics, economics with a health focus, or epidemiology with strong quantitative methods. Some roles accept a master's degree if paired with two or three years of modelling experience at a consulting firm, contract research organisation, or academic health economics unit. Alternative routes through biostatistics or health services research exist if you can demonstrate cost-effectiveness modelling skills through publications or previous projects.

Your first role is usually junior health economist or associate economist at a consultancy, pharmaceutical company, or academic centre. You replicate published models, conduct literature reviews, and assist on client projects under supervision. You learn the mechanics: how to source utility weights from EQ-5D catalogues, how to apply half-cycle corrections, how to structure a budget impact model for a US payer versus a European HTA body. Competence at this level is measured by whether your models run without error and whether your dossiers pass internal review before they leave the building.

Promotion to senior economist comes after you can lead a project from protocol to final report without significant revision. You design the model structure, defend methodological choices to clients, and review juniors' work. Principal economist roles involve multi-country submissions, original methodology development, and strategic advising on pricing and access strategy. Leadership positions like Director of HEOR or VP of Value and Access shift toward portfolio decisions, team management, and cross-functional work with clinical, regulatory, and commercial teams. Some people move into academia, health policy roles, or independent consulting after building a track record.

The profession grows as precision medicine and cell and gene therapies push traditional cost-effectiveness thresholds to their limits, and health systems worldwide demand evidence before they pay. If you want to see whether this kind of work matches the shape of your thinking, CareerMatch can hold it up against the rest of who you are.

From people doing the work

As a Health Economist, I spend a lot of time building complex models to evaluate the cost-effectiveness of new treatments or interventions. It's a mix of deep analytical work, statistical programming, and then translating those findings into clear, concise reports for decision-makers. You need to be comfortable with both the numbers and the narrative. It's to see your work directly influence healthcare policy and patient access.

Drawn from ISPOR conferences, Value in Health journal, Professional networking

Attribution: Composite

Composite · Synthesised from ISPOR, academic journals, 5-10 years experience

A day in the life of a Health Economist

People interaction: Moderate
Team vs solo: 45% Team / 55% Solo
Client facing: Sometimes
Impact visibility: High
Travel: Low-Moderate
Schedule flexibility: Flexible
Remote work: Fully Remote
Typical work hours: 42-48
Stress level: Moderate